[HTML] nature.com

[HTML][HTML] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - nature.com
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …
被引用次数：159 相关文章
[PDF] core.ac.uk

[PDF][PDF] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deicient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - core.ac.uk
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - …, 2020 - pubmed.ncbi.nlm.nih.gov
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …
[HTML] nih.gov

[HTML][HTML] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - ncbi.nlm.nih.gov
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - 2020 - repository.cam.ac.uk
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - go.gale.com
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The poly (ADP-ribose) polymerase (PARP)
inhibitor olaparib is FDA approved for the treatment of< jats: italic> BRCA</jats: italic> …

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - Oncogene, 2020 - europepmc.org
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …
[PDF] archive.org

[PDF][PDF] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deicient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - 2020 - scholar.archive.org
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …
[PDF] cam.ac.uk

[PDF][PDF] Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deicient cancer cells

RL Lloyd, PWG Wijnhoven, A Ramos-Montoya… - …, 2020 - repository.cam.ac.uk
The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the
treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits …